Clinical trial
Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell…
NCT00456833 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00456833 |
|---|---|
| Title | Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy |
| Official title | A Combined Phase 1 and 2 Study Investigating the Combination of RAD001 and Erlotinib in Patients With Advanced NSCLC Previously Treated Only With Chemotherapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | RAD001, erlotinib |
| Enrollment | 248 |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2011 |
| First posted | Apr 5, 2007 |
| Last update posted | Dec 21, 2020 |
| Countries | Canada, Denmark, France, Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: